Home › Funds › Decheng Capital LLC › NAMS

Decheng Capital LLC position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

Decheng Capital LLC reported holding 176,887 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$6.0M, representing 0.82% of its reported portfolio and ranking #12 among its reported holdings. Decheng Capital LLC has disclosed NAMS holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

Latest position (Q2 2026)176.89K sh
Reported value held$5.99M
Portfolio Weight0.82%
First reportedQ2 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Decheng Capital LLC's NAMS position evolved

Decheng Capital LLC first disclosed a stake in NAMS in Q2 2024 at 400,000 shares (US$7.7M). The position peaked in Q4 2025 at 592,057 shares, worth US$20.8M. Across 9 filings, Decheng Capital LLC increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 176,887 shares valued at US$6.0M — a reduction of -148,170 shares quarter over quarter.. Notable position changes include a 48% increase in Q3 2024 (shares rose 45% over the following quarter), a 45% trim in Q1 2026 (shares rose 12% over the following quarter), a 46% trim in Q2 2026 (shares fell 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 400.00K $7.68M New
Q3 2024 590.00K $9.79M Add
Q4 2024 770.00K $19.79M Add
Q1 2025 770.00K $15.76M Hold
Q2 2025 770.00K $13.94M Hold
Q3 2025 657.05K $18.69M Reduce
Q4 2025 592.06K $20.77M Reduce
Q1 2026 325.06K $10.41M Reduce
Q2 2026 176.89K $5.99M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 44 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has Decheng Capital LLC held NAMS?

Decheng Capital LLC has disclosed NAMS holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

What is Decheng Capital LLC's current position in NAMS?

As of Q2 2026, Decheng Capital LLC holds 176.89K shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $5.99M, representing 0.82% of its reported portfolio and ranking #12.

Has Decheng Capital LLC been buying or selling NAMS?

In the latest 13F filing (Q2 2026), Decheng Capital LLC reduced its position in NAMS. The position peaked in Q4 2025 at 592.06K shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.